Suscribirse

Prostate cancer in Korean men exhibits poor differentiation and is adversely related to prognosis after radical prostatectomy - 16/08/11

Doi : 10.1016/j.urology.2006.04.029 
Cheryn Song f, Jae Y. Ro a, Moo-Song Lee b, Sung-Joon Hong c, Byung-Ha Chung c, Han Yong Choi d, Sang-Eun Lee e, Eunsik Lee e, Choung-Soo Kim f, Hanjong Ahn f,
f Department of Urology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea 
a Department of Pathology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea 
b Department of Preventive Medicine, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea 
c Yonsei University College of Medicine, Severance Hospital, Seoul, Korea 
d Sungkyunkwan University School of Medicine, Samsung Medical Center, Seoul, Korea 
e Seoul National University College of Medicine, Seoul National University Hospital, Seoul, Korea 

Reprint requests: Hanjong Ahn, M.D., Department of Urology, University of Ulsan College of Medicine, Asan Medical Center, 388-1 Poongnap-dong, Songpa-gu, Seoul 138-736, Korea.

Abstract

Objectives

To investigate the clinical and pathologic characteristics of prostate cancer in Korean men to determine how ethnic differences affect clinical outcome.

Methods

The clinical and pathologic data of 604 Korean men who underwent radical prostatectomy from 1994 to 2003 were reviewed. Biochemical failure was defined as a prostate-specific antigen (PSA) level of 0.2 ng/mL or greater on two consecutive occasions after having achieved an undetectable PSA level. Patient distribution with respect to the clinical and pathologic parameters and biochemical failure rates were compared with those of contemporary Western series.

Results

The mean preoperative PSA level was 9.9 ng/mL (range 0.4 to 38.8) and the median biopsy Gleason score was 7. The Gleason score was 7 in 186 patients (30.8%) and greater than 7 in 169 (28.0%). Gleason scores stratified with respect to clinical stage and PSA range revealed the proportion of patients with high Gleason scores (7 or greater) to be more than 50% of each subgroup throughout the clinical stages and PSA ranges. At a median follow-up of 57.9 months (range 22 to 131), biochemical failure occurred in 24.2% of all patients and in 14.3% of those with an initial serum PSA level of 10.0 ng/mL or lower. On multivariate Cox regression analysis, the Gleason score showed the strongest statistical significance for biochemical failure (P = 0.001, hazard ratio 1.376, 95% confidence interval 1.056 to 1.792) for patients with a serum PSA level of 10.0 ng/mL or lower.

Conclusions

A significant proportion of prostate cancers arising in Korean men exhibit poor differentiation, regardless of the initial serum PSA level or clinical stage at presentation, and adversely affect prognosis, causing a greater rate of PSA failure.

El texto completo de este artículo está disponible en PDF.

Esquema


© 2006  Elsevier Inc. Reservados todos los derechos.
Añadir a mi biblioteca Eliminar de mi biblioteca Imprimir
Exportación

    Exportación citas

  • Fichero

  • Contenido

Vol 68 - N° 4

P. 820-824 - octobre 2006 Regresar al número
Artículo precedente Artículo precedente
  • Improved prostate cancer detection using systematic 14-core biopsy for large prostate glands with normal digital rectal examination findings
  • Masahiko Inahara, Hiroyoshi Suzuki, Satoko Kojima, Akira Komiya, Satoshi Fukasawa, Takashi Imamoto, Yukio Naya, Tomohiko Ichikawa
| Artículo siguiente Artículo siguiente
  • Mucinous adenocarcinoma of the prostate does not confer poor prognosis
  • Brian R. Lane, Cristina Magi-Galluzzi, Alwyn M. Reuther, Howard S. Levin, Ming Zhou, Eric A. Klein

Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
El acceso al texto completo de este artículo requiere una suscripción.

¿Ya suscrito a @@106933@@ revista ?

Mi cuenta


Declaración CNIL

EM-CONSULTE.COM se declara a la CNIL, la declaración N º 1286925.

En virtud de la Ley N º 78-17 del 6 de enero de 1978, relativa a las computadoras, archivos y libertades, usted tiene el derecho de oposición (art.26 de la ley), el acceso (art.34 a 38 Ley), y correcta (artículo 36 de la ley) los datos que le conciernen. Por lo tanto, usted puede pedir que se corrija, complementado, clarificado, actualizado o suprimido información sobre usted que son inexactos, incompletos, engañosos, obsoletos o cuya recogida o de conservación o uso está prohibido.
La información personal sobre los visitantes de nuestro sitio, incluyendo su identidad, son confidenciales.
El jefe del sitio en el honor se compromete a respetar la confidencialidad de los requisitos legales aplicables en Francia y no de revelar dicha información a terceros.


Todo el contenido en este sitio: Copyright © 2025 Elsevier, sus licenciantes y colaboradores. Se reservan todos los derechos, incluidos los de minería de texto y datos, entrenamiento de IA y tecnologías similares. Para todo el contenido de acceso abierto, se aplican los términos de licencia de Creative Commons.